{"podcast":{"title":"CNBC's \"Fast Money\"","slug":"cnbc-s-fast-money-385199","podcast_index_feed_id":385199,"rss_url":"https://feeds.simplecast.com/szW8tJ16","website_url":"https://www.cnbc.com","image_url":"https://image.simplecastcdn.com/images/92728f12-3d53-46b8-9a33-60e9b83ad72d/b76dd41f-8a3d-42e9-878f-e9bf9c8d572f/3000x3000/fast-money-podcast-cover-art-3000x3000-v05.jpg?aid=rss_feed","author":"CNBC","episode_count":2203,"summary":"Hosted by Melissa Lee and a roundtable of top traders, “Fast Money” breaks through the noise of the day, to deliver the actionable news that matters most to investors. Fast Money airs weeknights at 5p ET on CNBC. Visit http://fastmoney.cnbc.com for additional information.","last_synced_at":"2026-09-22T08:19:29.326583+00:00","page_url":"https://stenobird.com/podcast/cnbc-s-fast-money-385199"},"episode":{"title":"U.S. Banking Boom…And Record Stock Run for Kymera Therapeutics 7/7/26","slug":"u-s-banking-boom-and-record-stock-run-for-kymera-therapeutics-7-7-26","published_at":"2026-07-07T22:12:25+00:00","page_url":"https://stenobird.com/podcast/cnbc-s-fast-money-385199/u-s-banking-boom-and-record-stock-run-for-kymera-therapeutics-7-7-26","show_page_url":"https://stenobird.com/podcast/cnbc-s-fast-money-385199","url":"https://www.cnbc.com","audio_url":"https://dts.podtrac.com/redirect.mp3/cnbc.simplecastaudio.com/b7b89f33-e5b5-46a6-9e42-7f843e9567e5/episodes/320e9432-c10c-4b05-bd0a-fd1dd1a9071c/audio/128/default.mp3?aid=rss_feed&awCollectionId=b7b89f33-e5b5-46a6-9e42-7f843e9567e5&awEpisodeId=320e9432-c10c-4b05-bd0a-fd1dd1a9071c&feed=szW8tJ16","summary":"Financials surging as investors countdown to second quarter bank earnings next week, expecting major growth. The traders break down what the results could mean for these names and whether banks will see major gains. Then, shares of Kymera Therapeutics soaring as its Eczema drug trial timeline moves faster than expected. The firm’s founder, president and CEO Nello Mainolfi talks trial data and where the company is heading next. Plus, SpaceX stock plummeting despite bull calls on the Street, the media market under pressure, and Coke hitting all-time highs back to its century-old IPO. Fast Money Disclaimer","meta_description":"Financials surging as investors countdown to second quarter bank earnings next week, expecting major growth. The traders break down what the results could…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2626,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/cnbc-s-fast-money-385199/episodes/u-s-banking-boom-and-record-stock-run-for-kymera-therapeutics-7-7-26/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/cnbc-s-fast-money-385199/u-s-banking-boom-and-record-stock-run-for-kymera-therapeutics-7-7-26.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}